Skip to content
The Nexus
DossierENTITY

Brendan Smith

Coverage of Brendan Smith in the Nexus archive.

Earliest in view: Jul 20 · 09:30 UTCMost recent: Jul 20 · 09:30 UTC
Co-mentioned in this coverage
AItopic1drug developmenttopic1TD Cowenorganization1in silico platformstopic1computational toolstopic1Trump administrationorganization1Food and Drug Administrationorganization1
Recent coverage
  • HEALTHJul 20 · 09:30 UTCAXIOS
    How AI is supercharging drug development

    AI is accelerating drug development by reducing preclinical costs and timelines by up to 70%, according to a TD Cowen survey of biopharma leaders. The technology is driving demand for advanced software and computational tools to simulate biological processes and predict drug interactions, though no AI-discovered drug has yet received FDA approval.

Brendan Smith · Dossier · The Nexus